A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

NK/T Cell Lymphoma Nos Clinical Trial

Official title:
A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

Status Recruiting

Clinical Trial Summary

The purpose of this randomized, multi-center,phase Ⅲ clinical trail is to compare the safety and efficacy of sequencial chemoradiotherapy with or without toripalimab (PD-1 antibody) for newly diagnosed early-stage extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04365036
Study type	Interventional
Source	Sun Yat-sen University
Contact	Qingqing Cai, MD
Phone	0086-20-87342823
Email	caiqq@sysucc.org.cn
Status	Recruiting
Phase	Phase 3
Start date	May 2020
Completion date	June 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04127227` - Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type	Phase 2
Recruiting	`NCT04484506` - Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma	Phase 2
Not yet recruiting	`NCT05316246` - Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma	Phase 2
Recruiting	`NCT04231370` - Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma	Phase 2